Presentation is loading. Please wait.

Presentation is loading. Please wait.

Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews  Emily C. Merkel, Sandra A. Mitchell,

Published byΣπυριδούλα Βασιλικός Modified over 5 years ago

Similar presentations

Presentation on theme: "Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews  Emily C. Merkel, Sandra A. Mitchell,"— Presentation transcript:

1 Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews  Emily C. Merkel, Sandra A. Mitchell, Stephanie J. Lee  Biology of Blood and Marrow Transplantation  Volume 22, Issue 4, Pages (April 2016) DOI: /j.bbmt Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

2 Figure 1 Proportion of respondents endorsing any subscale symptoms, and the median and range of each subscale score among symptomatic patients. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

Download ppt "Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews  Emily C. Merkel, Sandra A. Mitchell,"

Similar presentations

Steven Joffe, Michelle M. Mello, E. Francis Cook, Stephanie J. Lee 

Steven Joffe, Michelle M. Mello, E. Francis Cook, Stephanie J. Lee 
Stephanie J. Lee, Loretta A. Williams 

Stephanie J. Lee, Loretta A. Williams 
Center for International Blood and Marrow Transplant Research Chronic Graft-versus- Host Disease Risk Score Predicts Mortality in an Independent Validation.

Center for International Blood and Marrow Transplant Research Chronic Graft-versus- Host Disease Risk Score Predicts Mortality in an Independent Validation.
Clinical Evaluation of Oral Chronic Graft-Versus-Host Disease

Clinical Evaluation of Oral Chronic Graft-Versus-Host Disease
How to Treat MDS without Stem Cell Transplantation

How to Treat MDS without Stem Cell Transplantation
Incidence and Prognostic Value of Eosinophilia in Chronic Graft-versus-Host Disease after Nonmyeloablative Hematopoietic Cell Transplantation  Imran Ahmad,

Incidence and Prognostic Value of Eosinophilia in Chronic Graft-versus-Host Disease after Nonmyeloablative Hematopoietic Cell Transplantation  Imran Ahmad,
Steven Joffe, Michelle M. Mello, E. Francis Cook, Stephanie J. Lee 

Steven Joffe, Michelle M. Mello, E. Francis Cook, Stephanie J. Lee 
Vaccination of Children following Allogeneic Stem Cell Transplantation

Vaccination of Children following Allogeneic Stem Cell Transplantation
Pharmacokinetics of Ganciclovir after Oral Valganciclovir versus Intravenous Ganciclovir in Allogeneic Stem Cell Transplant Patients with Graft-versus-Host.

Pharmacokinetics of Ganciclovir after Oral Valganciclovir versus Intravenous Ganciclovir in Allogeneic Stem Cell Transplant Patients with Graft-versus-Host.
Efficacy of Rituximab in the Setting of Steroid-Refractory Chronic Graft-versus-Host Disease: A Systematic Review and Meta-Analysis  Mohamed A. Kharfan-Dabaja,

Efficacy of Rituximab in the Setting of Steroid-Refractory Chronic Graft-versus-Host Disease: A Systematic Review and Meta-Analysis  Mohamed A. Kharfan-Dabaja,
David Myerson, Gideon Steinbach, Ted A. Gooley, Howard M. Shulman 

David Myerson, Gideon Steinbach, Ted A. Gooley, Howard M. Shulman 
Sympathectomy Protects Denervated Skin from Graft-Versus-Host Disease

Sympathectomy Protects Denervated Skin from Graft-Versus-Host Disease
Therapy of Sclerodermatous Chronic Graft-Versus-Host Disease with Mammalian Target of Rapamycin Inhibitors  Zuzana Jedlickova, Irina Burlakova, Gesine.

Therapy of Sclerodermatous Chronic Graft-Versus-Host Disease with Mammalian Target of Rapamycin Inhibitors  Zuzana Jedlickova, Irina Burlakova, Gesine.
Successful Treatment of Severe Acute Intestinal Graft-versus-Host Resistant to Systemic and Topical Steroids with Alemtuzumab  Marc Schnitzler, Jens Hasskarl,

Successful Treatment of Severe Acute Intestinal Graft-versus-Host Resistant to Systemic and Topical Steroids with Alemtuzumab  Marc Schnitzler, Jens Hasskarl,
Busulfan, Fludarabine, and Alemtuzumab As a Reduced Toxicity Regimen for Children with Malignant and Nonmalignant Diseases Improves Engraftment and Graft-versus-

Busulfan, Fludarabine, and Alemtuzumab As a Reduced Toxicity Regimen for Children with Malignant and Nonmalignant Diseases Improves Engraftment and Graft-versus-
Dasatinib as Salvage Therapy for Steroid Refractory and Imatinib Resistant or Intolerant Sclerotic Chronic Graft-versus-Host Disease  Isabel Sánchez-Ortega,

Dasatinib as Salvage Therapy for Steroid Refractory and Imatinib Resistant or Intolerant Sclerotic Chronic Graft-versus-Host Disease  Isabel Sánchez-Ortega,
Implementation of Post-Transplant Assessment Tools for Improved Accuracy of Graft- Versus-Host Disease Reporting  Madhu Ragupathi, Jaskiran Kaur, Luda.

Implementation of Post-Transplant Assessment Tools for Improved Accuracy of Graft- Versus-Host Disease Reporting  Madhu Ragupathi, Jaskiran Kaur, Luda.
Oral Manifestations Compatible with Chronic Graft-versus-Host Disease in Patients with Fanconi Anemia  Laura Grein Cavalcanti, Renata L. Fuentes Araújo,

Oral Manifestations Compatible with Chronic Graft-versus-Host Disease in Patients with Fanconi Anemia  Laura Grein Cavalcanti, Renata L. Fuentes Araújo,
Sabina Kersting, Leo F. Verdonck 

Sabina Kersting, Leo F. Verdonck 
Bisphosphonate Therapy for Reduced Bone Mineral Density in Children with Chronic Graft-versus-Host Disease  Paul A. Carpenter, Paul Hoffmeister, Charles.

Bisphosphonate Therapy for Reduced Bone Mineral Density in Children with Chronic Graft-versus-Host Disease  Paul A. Carpenter, Paul Hoffmeister, Charles.

Similar presentations

Ads by Google